Although this is a small study and will need a larger patient sample, our preliminary findings suggest that a 59% increase in [18F]FAZIN3 binding compared to that of the control subjects in a postmortem study may be a sufficient increase to detect changes in MAO-A levels in AD. This evidence concerns the gene MAOA and Alzheimer disease.